
2024 Healthcare Virtual Summit
Presented by Maxim Group
Hosted on M-Vest
2024 Healthcare Virtual Summit
October 15th at 9:00 AM ET
Presented by Maxim Group Hosted on M-Vest
Maxim Senior Analysts will host a wide range of biotechnology, diagnostic, medical device, and healthcare information technology companies in a series of presentations and interactive discussions with CEOs and key management. We also plan to host several topical industry panels that promise to be timely and engaging. To attend, just sign up to become an m-vest member and stay tuned for more updates!
B2I DIGITAL, Inc. is a marketing sponsor of the 2024 Maxim Healthcare Virtual Summit. B2I DIGITAL, Inc. is not an affiliate of Maxim Group and is not authorized to represent or act on behalf of Maxim Group, in any capacity. Maxim Group has not reviewed and approved the content contained on the b2idigital.com website. Content about any specific company was provided and approved by that company. B2I DIGITAL, Inc. has not independently verified the accuracy of the information contained herein. No content contained herein shall be considered an offer to solicit the sale of any security.
Unicycive Therapeutics, Inc.
Nasdaq: UNCY
OS Therapies, Inc.
NYSE American: OSTX
Acurx Pharmaceuticals, Inc.
Nasdaq: ACXP
Acurx Pharmaceuticals, Inc.
Nasdaq: ACXP
Acurx Pharmaceuticals is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. The Company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum (GPSS®) that blocks the active site of the Gram-positive specific bacterial enzyme DNA polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin- resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE), drug- resistant Streptococcus pneumoniae (DRSP) and B. anthracis (anthrax; a Bioterrorism Category A Threat-Level pathogen). Acurx's lead product candidate, ibezapolstat, for the treatment of C. difficile Infection is Phase 3 ready with plans in progress to begin international clinical trials. The Company's preclinical pipeline includes development of an oral product candidate for treatment of ABSSSI (Acute Bacterial Skin and Skin Structure Infections), upon which a development program for treatment of inhaled anthrax is being planned in parallel.
To learn more about Acurx Pharmaceuticals and its product pipeline, please visit www.acurxpharma.com.
Aethlon Medical
Nasdaq: AEMD
Aethlon Medical
Nasdaq: AEMD
Aethlon Medical, Inc. (Nasdaq: AEMD) is a clinical-stage medical device company headquartered in San Diego, California. Aethlon is advancing the Hemopurifier, to address unmet needs in oncology and infectious disease, using a novel platform designed to selectively remove circulation pathogenic targets from biologic fluids.
AIM ImmunoTech Inc.
NYSE American: AIM
AIM ImmunoTech Inc.
NYSE American: AIM
AIM ImmunoTech Inc. (NYSE American: AIM) is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
Alterity Therapeutics Limited
Nasdaq: ATHE
Alterity Therapeutics Limited
Nasdaq: ATHE
Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company’s lead asset, ATH434, has the potential to treat various forms of Parkinsonian disorders. Alterity also has a broad drug discovery platform generating patentable chemical to intercede in disease processes. Alterity is located in Melbourne, Australia and San Francisco, California, USA. The Company is listed on the Australian Securities Exchange (ASX: ATH) and NASDAQ (NASDAQ: ATHE).
Alzamend Neuro, Inc.
Nasdaq: ALZN
Alzamend Neuro, Inc.
Nasdaq: ALZN
Alzamend Neuro, Inc.
Alzamend Neuro® is a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease, Bipolar disorder, Major Depressive Disorder (“MDD”) and Post-Traumatic Stress Disorder (“PTSD”). Our mission is to rapidly develop and market safe and effective treatments to bring aid to the 43+ Million Americans suffering from these debilitating diseases. Our current pipeline consists of two novel therapeutic drug candidates, AL001 – a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and ALZN002 – a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer’s. Both of our product candidates are licensed from the University of South Florida Research Foundation, Inc. pursuant to royalty-bearing exclusive worldwide licenses.
Applied DNA Sciences, Inc.
APDN
Applied DNA Sciences, Inc.
APDN
Using our large scale polymerase chain reaction (PCR) based manufacturing platform, we manufacture large quantities of linear DNA for various markets. Whether for supply chain security, brand protection, law enforcement or drug candidate or biologic applications, it is our goal to help establish secure flourishing environments that foster quality, integrity and success.
Aprea Therapeutics, Inc. (NasdaqCM APRE)
Nasdaq: APRE
Aprea Therapeutics, Inc. (NasdaqCM APRE)
Nasdaq: APRE
Aprea Therapeutics, Inc. is a biopharmaceutical company headquartered in Doylestown, Pennsylvania, focused on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. The Company’s lead program is ATRN-119, a Phase 1-ready small molecule ATR inhibitor being developed for solid tumor indications.
Artelo Biosciences, Inc.
Nasdaq: ARTL
Artelo Biosciences, Inc.
Nasdaq: ARTL
Artelo Biosciences is a clinical stage company using cutting-edge science to improve patient care.
We were founded in 2017 on the promise of therapeutic development based on lipid-signaling modification, including targeting the receptors of the endocannabinoid system.
Our mission is to alter the course of treatment for those with a diagnosis of cancer and other serious conditions.
Assertio Holdings, Inc.
Nasdaq: ASRT
Assertio Holdings, Inc.
Nasdaq: ASRT
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients and has a robust portfolio of branded prescription products in neurology, oncology, hospital and pain and inflammation. The Company has grown through business development including licensing, mergers, and acquisitions and is interested in products across all therapeutic areas, including our current focus.
Atai Life Sciences
Nasdaq: ATAI
Atai Life Sciences
Nasdaq: ATAI
Atai Life Sciences is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.
We founded atai in 2018 as a response to the significant unmet need and lack of innovation in the mental health treatment landscape, as well as the emergence of therapies that previously may have been overlooked or underused, including psychedelic compounds and digital therapeutics.
Autonomix Medical, Inc.
Nasdaq: AMIX
Autonomix Medical, Inc.
Nasdaq: AMIX
Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in The Woodlands, TX. (Source: www.tradingview.com 02.21.26)
Avenue Therapeutics
Nasdaq: ATXI
Avenue Therapeutics
Nasdaq: ATXI
Avenue Therapeutics, Inc. (Nasdaq: ATXI) is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases. The Company is currently developing three assets including AJ201, a first-in-class asset for spinal and bulbar muscular atrophy, BAER-101, an oral small molecule selective GABA-A α2/3 receptor positive allosteric modulator for CNS diseases, and IV Tramadol, which is in Phase 3 clinical development for the management of moderate-to-moderately-severe pain in adults in a medically supervised healthcare setting. Avenue is headquartered in Miami, FL and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). For more information, visit www.avenuetx.com.
Aytu BioPharma, Inc.
Nasdaq: AYTU
Aytu BioPharma, Inc.
Nasdaq: AYTU
Aytu BioPharma is a pharmaceutical company developing and commercializing novel therapeutics. Our company’s evolution has been driven by strategic in-licensing and acquisition-based transactions and organic product growth. As we continue this trajectory, we are also building a complementary novel therapeutic development pipeline addressing significant unmet needs in rare and complex diseases.
Azitra, Inc.
NYSE American: AZTR
Azitra, Inc.
NYSE American: AZTR
Azitra is a pioneer in genetically engineered bacteria and proteins for therapeutic use in dermatology. Azitra leverages proprietary platforms and an internal microbial library to create new therapeutics that are either engineered living organisms or engineered proteins or peptides to treat skin diseases. Azitra has built a proprietary platform that includes a microbial library comprised of approximately 1,500 unique bacterial strains that can be screened for unique therapeutic characteristics. The platform is augmented by an artificial intelligence and machine learning technology that analyzes, predicts, and helps screen Azitra’s library of strains for drug like molecules. The platform also utilizes a licensed genetic engineering technology, which can enable the transformation of previously genetically intractable strains. Azitra’s initial focus is on the development of genetically engineered strains of Staphylococcus epidermidis. Azitra’s lead therapeutic candidates are ATR-12, a genetically modified strain of S. epidermidis for treating the orphan disease Netherton syndrome, and ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor, or EGFRi, targeted therapy.
Belite Bio, Inc.
Nasdaq: BLTE
Belite Bio, Inc.
Nasdaq: BLTE
We are a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting currently retinal degenerative eye diseases with have significant unmet medical needs, such as Stargardt disease (STGD1) or Geographic Atrophy (GA) in advanced dry age-related macular degeneration (dry AMD), in addition to specific metabolic diseases.
We believe our lead product candidate, Tinlarebant, or LBS-008 if approved, would provide a novel treatment option where there currently is none. Tinlarebant is novel oral therapy which is intended to reduce the accumulation of toxins in the eye that cause STGD1 and contribute to GA, or advanced dry AMD. These toxins are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of these toxins. In clinical trials, Tinlarebant has demonstrated its target specificity and potency that we believe could be clinically meaningful to treat STGD1 patients.
We have completed a two-year Phase 2 study of Tinlarebant in adolescent STGD1 subjects, and are conducting a Phase 3 study (DRAGON) and a Phase 2/3 study (DRAGON II) in adolescent STGD1 subjects and a Phase 3 study (PHOENIX) in subjects with GA. DRAGON study is a multi-center, randomized, double masked, placebo controlled study to evaluate the safety and efficacy of Tinlarebant in the treatment of adolescent STGD1 patients. DRAGON II trial is a combination of phase 1b open-label study to evaluate the pharmacokinetics and pharmacodynamics of Tinlarebant in Japanese adolescent STGD1 subjects and a phase 2/3, multicenter, double-masked, placebo-controlled, randomized study designed to evaluate the efficacy, safety and tolerability of Tinlarebant in adolescent STGD1 subjects. PHOENIX study is a multi-center, randomized, double‐masked, placebo-controlled study to evaluate the safety and efficacy of Tinlarebant in GA subjects.
bioAffinity Technologies, Inc.
Nasdaq: BIAF
bioAffinity Technologies, Inc.
Nasdaq: BIAF
bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths, with the potential to dramatically increase overall diagnostic accuracy of lung cancer leading to increased survival, fewer unnecessary invasive procedures, reduced patient anxiety, and lower medical costs.
Bionomics Limited
Nasdaq: BNOX
Bionomics Limited
Nasdaq: BNOX · OTCQB: BNOEF
Bionomics (NASDAQ:BNOX, OTCQB:BNOEF) Bionomics is currently based in Australia and the US and trades in the US on NASDAQ Global Market (NASDAQ) under the ticker “BNOX”.
BioRestorative Therapies, Inc.
Nasdaq: BRTX
BioRestorative Therapies, Inc.
Nasdaq: BRTX
BioRestorative Therapies was founded by scientists and researchers committed to developing stem cell therapies to address unmet needs in patients with highly prevalent conditions.
Our advances in stem cell biology and delivery protocols harbor great promise in conditioning our bodies’ own regenerative potential to treat major diseases more effectively than current interventions.
Brainstorm Cell Therapeutics Inc.
Nasdaq: BCLI
Brainstorm Cell Therapeutics Inc.
Nasdaq: BCLI
BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Alzheimer’s Disease (AD).
Chemomab Therapeutics Ltd.
Nasdaq: CMMB
Chemomab Therapeutics Ltd.
Nasdaq: CMMB
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need.
Based on the unique and pivotal role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a monoclonal antibody that neutralizes CCL24 activity. In clinical and preclinical studies, CM-101 appears safe and has demonstrated the potential to treat multiple severe and life-threatening fibro-inflammatory diseases.
Chemomab has reported positive results from three clinical trials of CM-101 completed to date. A Phase 2 trial in the rare liver disease primary sclerosing cholangitis (PSC) has completed patient enrollment, with topline data expected midyear 2024.
Citius Pharmaceuticals, Inc.
Nasdaq: CTXR
Citius Pharmaceuticals, Inc.
Nasdaq: CTXR
Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) is a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products. Citius Pharma owns approximately 74.8% of Citius Oncology. In December 2025, Citius Oncology launched LYMPHIR, a targeted immunotherapy for the treatment of adults with relapsed or refractory Stage I–III CTCL who had had at least one prior systemic therapy. Citius Pharma's late-stage pipeline also includes Mino-Lok®, a catheter lock solution to salvage catheters in patients with catheter-related bloodstream infections, and CITI-002 (Halo-Lido), a topical formulation for the relief of hemorrhoids. A pivotal Phase 3 trial for Mino-Lok and a Phase 2b trial for Halo-Lido were completed in 2023. Mino-Lok met primary and secondary endpoints of its Phase 3 trial. Citius Pharma is actively engaged with the FDA to outline next steps for both programs. For more information, please visit www.citiuspharma.com.
Clene Inc.
Nasdaq: CLNN
Clene Inc.
Nasdaq: CLNN
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
(Source: www.tradingview.com 07.28.26)
CNS Pharmaceuticals, Inc.
Nasdaq: CNSP
CNS Pharmaceuticals, Inc.
Nasdaq: CNSP
CNS Pharmaceuticals (Nasdaq: CNSP) is a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system.
The Company's lead drug candidate, Berubicin, is the first anthracycline to appear to cross the blood-brain barrier. Berubicin is the subject of the Company's late-stage, fully-enrolled, global clinical trial for the treatment of glioblastoma multiforme (GBM), an aggressive and currently incurable form of brain cancer. The Company expects to release primary analysis data on Berubicin's performance in this designed-to-be pivotal trial before the end of the first quarter of 2025.
The Company's second drug candidate, TPI 287, is an abeotaxane which stabilizes microtubules and inhibits cell division, causing apoptosis and cell death. Similar to Berubicin, TPI 287 has shown the potential to cross the blood-brain barrier and treat CNS tumors. TPI 287 has been well tolerated in over 350 patients to date, including in clinical trials as a monotherapy and in combination with bevacizumab for the treatment of recurrent neuroblastoma and medulloblastoma, as well as refractory prostate cancer and melanoma, and in tauopathy disease, which can result in dementia.
For more information, please visit www.CNSPharma.com, and connect with the Company on X, Facebook, and LinkedIn.
Context Therapeutics Inc. (NasdaqCM CNTX)
Nasdaq: CNTX
Context Therapeutics Inc. (NasdaqCM CNTX)
Nasdaq: CNTX
Context Therapeutics Inc. (Nasdaq: CNTX) is a biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies for solid tumors. Context is building an innovative portfolio of TCE bispecific therapeutics, including CTIM-76, a Claudin 6 x CD3 bispecific antibody, CT-95, a Mesothelin x CD3 bispecific antibody, and CT-202, a Nectin-4 x CD3 bispecific antibody. Context is headquartered in Philadelphia. For more information, please visit www.contexttherapeutics.com or follow the Company on X (formerly Twitter) and LinkedIn.
Daxor Corporation
Nasdaq: DXR
Daxor Corporation
Nasdaq: DXR
Daxor Corporation (Nasdaq: DXR) is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100TM (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. The BVA technology enhances hospital performance metrics in a broad range of surgical and medical conditions, including heart failure and critical care, by informing treatment strategies, resulting in significantly improved multiple measures of patient outcomes. Daxor’s mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all.
Dermata Therapeutics, Inc.
Nasdaq: DRMA
Dermata Therapeutics, Inc.
Nasdaq: DRMA
We are a clinical-stage biotechnology company founded in 2014 focused on developing and commercializing products for the treatment of various skin disease and multiple aesthetic skin conditions. Our current product pipeline is comprised of topical treatment product candidates derived from our Spongilla platform technology which we believe have the potential to address the multiple facets of acne, psoriasis, hyperhidrosis, and multiple aesthetic areas.
Our lead product candidate, DMT310, is currently in development for the once-weekly treatment of moderate-to-severe acne. It is our first product candidate being developed from our Spongilla platform to treat both the inflammatory and noninflammatory lesions of acne by utilizing our technology’s unique mechanical and chemical components. We have completed a successful Phase 2b trial of DMT310 for the treatment of moderate to severe acne where we achieved statistically significant results for all end points as early as week 4 and continuing until the end of study at week 12. In addition to the DMT310 program we also have a secondary product, DMT410, which utilizes our Spongilla technology to aid in the topical delivery of large molecules, such as botulinum toxin for the treatment of various skin diseases and aesthetic conditions. We have completed two Phase 1, proof of concept study of DMT410 for the treatment of hyperhidrosis and various aesthetic conditions and are currently discussing partnerships with a botulinum toxin company.
electroCore, Inc.
Nasdaq: ECOR
electroCore, Inc.
Nasdaq: ECOR
electroCore is a bioelectronic technology company whose mission is to improve health and quality of life through innovative non-invasive bioelectronic technologies. The Company’s two leading prescription products to treat chronic pain syndromes through non-invasive neuromodulation technology are gammaCore non-invasive vagus nerve stimulation, or nVNS, and the Quell® Fibromyalgia. Additionally, the Company commercializes its handheld and personal use Trvuaga and TAC-STIM nVNS products utilizing bioelectronic technologies to promote general wellness and human performance.
Femasys Inc.
Nasdaq: FEMY
Femasys Inc.
Nasdaq: FEMY
Femasys Inc. is a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health.
Fennec Pharmaceuticals
Nasdaq: FENC
Fennec Pharmaceuticals
Nasdaq: FENC · TSX: FRX
Fennec Pharmaceuticals Inc., (NASDAQ: FENC; TSX: FRX) is a commercial stage specialty pharmaceutical company focused on the development of PEDMARK® (sodium thiosulfate injection). PEDMARK is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients with localized, non-metastatic solid tumors. In October 2022, Fennec commercially launched PEDMARK in the United States.
PEDMARK received Orphan Drug designation by the FDA in 2004. The Marketing Authorization Application (MAA) for sodium thiosulfate (tradename PEDMARQSI) is currently under evaluation by the European Medicines Agency (EMA).
FibroBiologics, Inc.
Nasdaq: FBLG
FibroBiologics, Inc.
Nasdaq: FBLG
FibroBiologics is a cell therapy, regenerative medicine company developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 150+ US and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy.
Gain Therapeutics, Inc.
Nasdaq: GANX
Gain Therapeutics, Inc.
Nasdaq: GANX
Gain Therapeutics, Inc. is a clinical-stage biotechnology company leading the discovery and development of next generation allosteric therapies. Gain's lead drug candidate GT-02287 for the treatment of Parkinson's disease and other neurodegenerative diseases is currently being evaluated in a Phase 1 clinical trial. With its Magellan drug discovery platform, Gain is transforming drug discovery by integrating Al, physics-based methods and supercomputing power to discover novel allosteric binding sites and potential first-in-class drug candidates from on-demand libraries with 50 billion compounds in less than 3 months. (Source: www.tradingview.com 07.06.26)
Genelux Corporation
Nasdaq: GNLX
Genelux Corporation
Nasdaq: GNLX
Genelux is a Phase 3 biopharmaceutical company developing powerful therapeutics for patients suffering from difficult-to-treat cancers. The Company is focused on the development of next-generation oncolytic viral immunotherapies that are designed to generate a personalized multi-prong attack to overwhelm a tumor’s sophisticated defense mechanisms.
Genenta Science S.p.A.
Nasdaq: GNTA
Genenta Science S.p.A.
Nasdaq: GNTA
Genenta is a clinical stage immuno-oncology company developing a cell-based platform harnessing the power of hematopoietic stem cells to provide durable and safe treatments for solid tumors.
Our platform is not tumor type nor target antigen restricted and provides sustained targeted expression of therapeutic payload(s) inside the tumor micro environment.
Genenta’s lead product candidate, TemferonTM, precisely targets the delivery of interferon-alpha to the tumor micro-environment, minimizing systemic toxicity while breaking tumor-induced immune tolerance.
Our treatments are designed as one-time monotherapies, but with the additional potential, when used in combination, to significantly enhance the efficacy of other approved therapeutics.
IceCure Medical Ltd.
Nasdaq: ICCM
IceCure Medical Ltd.
Nasdaq: ICCM · TASE: ICCM
IceCure is transforming healthcare by bringing the choice of advanced minimally invasive cryoablation treatment options for benign and malignant tumors to women's health and interventional oncology.
Immuron Limited
Nasdaq: IMRN
Immuron Limited
Nasdaq: IMRN
Immuron Limited is a commercial and clinical stage publicly listed Australian biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of specifically targeted polyclonal antibodies that we believe can address significant unmet medical needs. The company was incorporated under the laws of Australia in 1994 and has been listed on the Australian Securities Exchange (ASX), since April 30, 1999 and our ordinary shares trade under the symbol “IMC.”. Immuron completed an initial public offering on the NADAQ Capital Market in June 2017 and our American Depositary Shares and warrants are listed on NASDAQ under the symbols “IMRN” and “IMRNW”, respectively. Each ADS represents 40 of our ordinary shares, no par value.
Our validated technology platform can produce orally active polyclonal antibodies which offer targeted delivery within the gastrointestinal (“GI”) tract and essentially do not cross into the bloodstream. We believe that our lead drug candidates, currently in clinical development, have the potential to transform the existing treatment paradigms for moderate to severe Campylobacteriosis, Clostridiodes difficile infections, Enterotoxigenic Escherichia coli (ETEC) infections and travelers’ diarrhea, a digestive tract disorder that is commonly caused by pathogenic bacteria and the toxins they produce.
We currently market our flagship commercial products Travelan® and Protectyn® in Australia, where both products are listed medicines on the Australian Register for Therapeutic Goods. Travelan® (AUST L 106709) is an over-the-counter orally administered passive immunotherapeutic product indicated to reduce the risk of travelers’ diarrhea, reduce the risk of minor gastro-intestinal disorders and is antimicrobial. It is sold in pharmacies throughout Australia. Protectyn® (AUST L 231001) is currently sold in practitioners’ offices and is marketed as an immune supplement to help maintain a healthy digestive function and liver. We also market Travelan® in Canada (NPN 80046016) where it is licensed as a natural health product indicated to reduce the risk of travelers’ diarrhea, and presently market Travelan® in the U.S. as a dietary supplement for digestive tract protection.
Indaptus Therapeutics, Inc.
Nasdaq: INDP
Indaptus Therapeutics, Inc.
Nasdaq: INDP
Indaptus Therapeutics, Inc. (Nasdaq: INDP) has evolved from more than a century of immunotherapy advances. The Company’s novel approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Indaptus’ patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The product candidates are designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cells and pathways of innate and adaptive immunity. Decoy product candidates represent an antigen-agnostic technology that have produced single-agent activity against metastatic pancreatic and orthotopic colorectal carcinomas, single agent eradication of established antigen-expressing breast carcinoma, as well as combination-mediated eradication of established hepatocellular carcinomas, pancreatic and non-Hodgkin’s lymphomas in standard pre-clinical models, including syngeneic mouse tumors and human tumor xenografts. In pre-clinical studies tumor eradication was observed with Decoy product candidates in combination with anti-PD-1 checkpoint therapy, low-dose chemotherapy, a non-steroidal anti-inflammatory drug, or an approved, targeted antibody. Combination-based tumor eradication in pre-clinical models produced innate and adaptive immunological memory, involved activation of both innate and adaptive immune cells, and was associated with induction of innate and adaptive immune pathways in tumors after only one i.v. dose of Decoy product, with associated “cold” to “hot” tumor inflammation signature transition. IND-enabling, nonclinical toxicology studies demonstrated i.v. administration without sustained induction of hallmark biomarkers of cytokine release syndromes, possibly due to passive targeting to liver, spleen, and tumor, followed by rapid elimination of the product. Indaptus’ Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Inhibikase Therapeutics, Inc.
Nasdaq: IKT
Inhibikase Therapeutics, Inc.
Nasdaq: IKT
Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, The Company’s pipeline includes multiple product candidates developed from its proprietary RAMP drug innovation and prodrug technology engines, using the same clinically validated kinase target. The Company is headquartered in Atlanta with additional offices in Lexington, Massachusetts.
INmune Bio, Inc.
Nasdaq: INMB
INmune Bio, Inc.
Nasdaq: INMB
INmune Bio Inc. is a publicly traded (Nasdaq: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) product platform utilizes dominant-negative technology to selectively neutralize soluble TNF, a key driver of innate immune dysfunction and a mechanistic driver of many diseases. DN-TNF product candidates are in clinical trials to determine if they can treat Mild Alzheimer’s disease, Mild Cognitive Impairment and treatment-resistant depression (XProTM). The Natural Killer Cell Priming Platform includes INKmune® developed to prime a patient’s NK cells to eliminate minimal residual disease in patients with cancer and is currently in trials in metastatic castration-resistance prostate cancer. The third program, CORDStrom, is a proprietary pooled, allogeneic, human umbilical cord-derived mesenchymal Stromal/Stem cell (hucMSCs) platform that recently completed a blinded randomized trial in recessive dystrophic epidermolysis bullosa. INmune Bio’s product platforms utilize a precision medicine approach for diseases driven by chronic inflammation and cancer. To learn more, please visit www.inmunebio.com.
Iterum Therapeutics plc
ITRM
Iterum Therapeutics plc
ITRM
Iterum Therapeutics plc is an Ireland-based clinical-stage pharmaceutical company dedicated to developing differentiated anti-infectives. These products are aimed at combating the global crisis of multi-drug resistant (MDR) pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. Iterum’s first product is a novel anti-infective compound that has demonstrated potent in-vitro activity vs. a wide variety of gram-negative, gram-positive and anaerobic bacteria resistant to other antibiotics.
Kairos Pharma, Ltd.
NYSE American: KAPA
Kairos Pharma, Ltd.
NYSE American: KAPA
Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs.
Kazia Therapeutics Limited
Nasdaq: KZIA
Kazia Therapeutics Limited
Nasdaq: KZIA
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed Phase 2/3 study in glioblastoma (GBM-Agile) was reported in 2024, and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval. Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. In addition to its clinical-stage programs, Kazia is advancing NDL2, a potentially first-in-class nuclear PD-L1 protein degrader program targeting a newly identified mechanism of immunotherapy resistance and metastatic progression, currently in preclinical development. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx.
Kiora Pharmaceuticals, Inc.
Nasdaq: KPRX
Kiora Pharmaceuticals, Inc.
Nasdaq: KPRX
Kiora Pharmaceuticals (Nasdaq: KPRX) is a clinical-stage biotechnology company developing advanced therapies for retinal disease. We target critical pathways underlying retinal diseases using innovative small molecules to slow, stop, or restore vision loss. KIO-301 is being developed for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of retinal inflammation. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase (DHODH).
In addition to news releases and SEC filings, we expect to post information on our website, www.kiorapharma.com, and social media accounts that could be relevant to investors. We encourage investors to follow us on X and LinkedIn as well as to visit our website and/or subscribe to email alerts.
Lexaria Bioscience Corp.
Nasdaq: LEXX
Lexaria Bioscience Corp.
Nasdaq: LEXX
Lexaria Bioscience Corp.'s patented drug delivery technology, DehydraTECHTM, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting more effective oral delivery.
Testing conducted since 2016 has repeatedly demonstrated DehydraTECH has the ability to:
Increase bio-absorption many-fold compared to standard industry formulations
Reduce time of onset from 1 – 2 hours to minutes
Deliver drugs more effectively across the blood brain barrier, and
Improve tolerability
It is also being evaluated for hypertension, GLP-1 drugs and more.
Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 46 patents granted and many more patents pending worldwide.
Lexaria operates five subsidiary companies to focus on its different commercial opportunities in their respective industries:
Lexaria Pharmaceutical Corp. investigates new pharmaceutical applications for hypertension, antiviral treatments, epilepsy and other drug classes
Lexaria Nicotine LLC investigates oral non-combusted product formats
Lexaria Hemp Corp. pursues business-to-business opportunities with hemp-derived ingredients
Lexaria Canpharm ULC operates a state-of-the-art Health Canada licensed laboratory capable of developing novel cannabinoid and other formulations for potential commercialization
Lexaria Nutraceutical Corp. explores applications of DehydraTECH for the consumer-packaged goods sector
Lexaria sub-licenses the Company’s DehydraTECH technology worldwide for the delivery of fat-soluble active molecules and drugs.
Lineage Cell Therapeutics, Inc.
NYSE: LCTX
Lineage Cell Therapeutics, Inc.
NYSE: LCTX
Lineage’s programs are based on the Company’s proprietary cell-based therapy platform and associated development and manufacturing capabilities. With our platform we develop and manufacture specialized, terminally-differentiated human cells from our pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer.
Lipella Pharmaceuticals Inc.
Nasdaq: LIPO
Lipella Pharmaceuticals Inc.
Nasdaq: LIPO
Lipella Pharmaceuticals Inc. is a clinical-stage biotechnology company focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. Our proprietary liposomal formulations are optimized for the delivery of agents to mucosal tissue, such as the oral cavity and the bladder lumen. Our pharmaceutical assets include a phase 2 program in oral lichen planus, and a phase 2 program in hemorrhagic cystitis.
Lucid Diagnostics Inc.
Nasdaq: LUCD
Lucid Diagnostics Inc.
Nasdaq: LUCD
Lucid Diagnostics Inc., markets the first and only commercial tools for widespread early detection of esophageal precancer and cancer – the EsoGuard® Esophageal DNA Test and EsoCheck® Esophageal Cell Collection Device.
Medicus Pharma Ltd.
Nasdaq: MDCX
Medicus Pharma Ltd.
Nasdaq: MDCX · TSXV: MDCX
Medicus Pharma Ltd. (Nasdaq: MDCX) is a precision-guided biotech company advancing novel therapeutic assets.
Its lead asset, CD228V ADC, is an investigational antibody-drug conjugate targeting CD228 across multiple solid tumors, that the company is co-developing with Pfizer.
The pipeline also includes:
SkinJect® is a localized immuno-oncology product being evaluated to treat multiple basal cell carcinoma lesions in Gorlin Syndrome patients, a rare autosomal dominant genetic disorder.
Teverelix®, a next-generation GnRH antagonist targeting cardiovascular high-risk prostate cancer, acute urinary retention relapse, and endometriosis.
Medicus’ strategy is to advance select programs through Phase 2 proof-of-concept to reduce development risk and increase their attractiveness to potential partners. The Company is exploring opportunities for strategic collaborations and sub-licensing transactions.
Medivir AB
MVIR
Medivir AB
MVIR
Medivir is a pharmaceutical company focusing on the development and commercialization of innovative treatments for cancer.
MediWound Ltd.
Nasdaq: MDWD
MediWound Ltd.
Nasdaq: MDWD
MediWound Ltd. (Nasdaq: MDWD) is the global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that improve existing standards of care and patient experiences, while reducing costs and unnecessary surgeries.
Mesoblast Limited
Nasdaq: MESO
Mesoblast Limited
Nasdaq: MESO
Mesoblast is using its proprietary technology platform to develop and commercialize innovative allogeneic cellular medicines to treat complex diseases resistant to conventional standard of care and where inflammation plays a central role.
The Company’s portfolio of Phase 3 product candidates comprises remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD), and for moderate to severe acute respiratory distress syndrome (ARDS) due to COVID-19 infection; REVASCOR® for advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Milestone Scientific Inc.
NYSE: MLSS
Milestone Scientific Inc.
NYSE: MLSS
Milestone Scientific is committed to advancing the science of computer-controlled drug delivery systems that offer significant efficiency and patient comfort gains for the medical and dentistry fields.
Moleculin Biotech, Inc.
Nasdaq: MBRX
Moleculin Biotech, Inc.
Nasdaq: MBRX
Moleculin Biotech, Inc. is a Phase 3 clinical stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing hard-to-treat tumors and viruses. The Company’s lead program, Annamycin (also known as naxtarubicin), is a highly efficacious and well tolerated anthracycline designed to avoid multidrug resistance mechanisms and to lack the cardiotoxicity common with currently prescribed anthracyclines. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.
Myomo, Inc.
NYSE: MYO
Myomo, Inc.
NYSE: MYO
Based on patented technology developed at MIT, Harvard Medical School and by the Company, Myomo develops and markets the MyoPro® product line of lightweight, non-invasive, powered arm braces (orthoses) to restore function in the paralyzed or weakened arms and hands of individuals that have suffered a stroke, spinal cord or nerve injury such as brachial plexus injury, or other neuro-muscular disabilities. It is the only device that, sensing a patient’s own neurological signals through non-invasive sensors on the arm, can restore their ability to use their arms and hands so that they can return to work, live independently and reduce their cost of care. Published clinical research shows a clinically significant instantaneous reduction in upper extremity impairment through the use of MyoPro. MyoPro is referred for patients at leading rehabilitation facilities, including Mayo Clinic, Cleveland Clinic, Massachusetts General Hospital, Kennedy Krieger Institute, Loma Linda Medical Center and twenty VA hospitals, among others. It is fitted and delivered through a nationwide network of orthotics and prosthetics practices, and over 600 have been used by patients. Myomo is headquartered in Boston, Massachusetts, with sales and clinical professionals across the U.S.
NeuroBo Pharmaceuticals, Inc.
NRBO
NeuroBo Pharmaceuticals, Inc.
NRBO
NeuroBo Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type 2 Diabetes Mellitus (T2DM), and is developing DA-1726 for the treatment of obesity. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In preclinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus potentially resulting in superior body weight loss compared to selective GLP1R agonists.
NEXGEL, Inc.
Nasdaq: NXGL
NEXGEL, Inc.
Nasdaq: NXGL
NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.
Numinus Wellness Inc.
TSX: NUMI
Numinus Wellness Inc.
TSX: NUMI · OTCQX: NUMIF, TSE: NUMI
Numinus is an integrated mental health company creating an ecosystem of health solutions to research, develop, and deliver safe, evidence-based, accessible psychedelic-assisted psychotherapy.
Nutex Health Inc.
Nasdaq: NUTX
Nutex Health Inc.
Nasdaq: NUTX
Nutex Health Inc. is a technology-enabled healthcare services company with two divisions: a Hospital Division and a Population Health Management Division.
The Hospital Division implements and operates innovative health care models, including micro-hospitals, specialty hospitals, and hospital outpatient departments (HOPDs). This division owns and operates 21 facilities in 8 states.
The Population Health Management Division owns and operates provider networks such as Independent Physician Associations (IPAs). Our Management Services Organizations (MSOs) provide management, administrative, and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates data across multiple information systems, settings, and sources to create a holistic view of each patient and provider, allowing us to deliver greater quality care more efficiently.
Ocugen, Inc.
Nasdaq: OCGN
Ocugen, Inc.
Nasdaq: OCGN
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs.
Oncolytics Biotech Inc.
Nasdaq: ONCY
Oncolytics Biotech Inc.
Nasdaq: ONCY
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastatic breast cancer and pancreatic cancer, indications with continued and considerable unmet needs. Based on very compelling data, Oncolytics believes that advancing pelareorep through late-stage clinical testing, submission and registration in these indications present the highest chance of success with the greatest commercial opportunity.
Oragenics, Inc.
NYSE: OGEN
Oragenics, Inc.
NYSE: OGEN
Oragenics, Inc. is a development-stage company dedicated to fighting infectious diseases including coronaviruses and multidrug-resistant organisms. Its lead product is Terra CoV-2, an intranasal vaccine candidate to prevent COVID-19 and variants of the SARS-CoV-2 virus. The Terra CoV-2 program leverages coronavirus spike protein research licensed from the NIH and the NRC with a focus on reducing viral transmission and offering a more patient-friendly intranasal administration. Its lantibiotics program features a novel class of antibiotics against bacteria that have developed resistance to commercial antibiotics. In October of 2023, Oragenics announced the signing of a definitive agreement with Odyssey Health, Inc. to acquire assets related to their proprietary neurological drug therapies, including their proprietary formulation and nasal delivery system. The assets include drug candidates for treating mild traumatic brain injury, also known as concussion, and for treating Niemann Pick Disease Type C.
Palisade Bio, Inc.
Nasdaq: PALI
Palisade Bio, Inc.
Nasdaq: PALI
Palisade Bio is a biopharmaceutical company dedicated to advancing next-generation precision therapies for immune, inflammatory, and fibrotic diseases. These conditions represent a significant unmet need, leading to chronic organ dysfunction, damage and even failure due to abnormal immune responses and persistent inflammation.
Our lead program, PALI-2108, is a microbiota-activated PDE4 inhibitor prodrug in development for the treatment of moderate-to-severe ulcerative colitis. Ulcerative colitis represents a significant challenge for patients, who are in need of therapies that provide effective remission rates, are non-immunosuppressive and have improved safety.
Quince Therapeutics, Inc.
QNCX
Quince Therapeutics, Inc.
QNCX
Quince Therapeutics, Inc. is a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases. Our Phase 3 lead asset, EryDex, for the treatment of the rare pediatric neurodegenerative disease Ataxia-Telangiectasia (A-T) is the first product in development that leverages our proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient’s own red blood cells. EryDex is comprised of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells and is designed to maintain the efficacy of corticosteroids but reduce or eliminate the significant adverse effects associated with corticosteroid treatment. We are currently enrolling a pivotal Phase 3 NEAT clinical trial evaluating the neurological effects of EryDex in patients with A-T and topline results from the study are expected in the fourth quarter of 2025. For more information and the latest news on the company, visit www.quincetx.com and follow Quince on social media platforms LinkedIn, Facebook, X, and YouTube.
Quoin Pharmaceuticals, Ltd.
Nasdaq: QNRX
Quoin Pharmaceuticals, Ltd.
Nasdaq: QNRX
Rare diseases are only rare if you don’t live with one.TM
Quoin is a clinical stage specialty pharmaceutical company focused on the development of therapeutic products for rare and orphan diseases.
We are dedicated to supporting underserved patients and their families, communities, and care teams around the world.
Rani Therapeutics Holdings, Inc.
Nasdaq: RANI
Rani Therapeutics Holdings, Inc.
Nasdaq: RANI
Rani is a clinical stage biotherapeutics company advancing technologies to enable the development of orally administered biologics, which we believe will have the potential to transform medicine and improve patient outcomes. We have developed the RaniPill capsule, which is our novel, proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The RaniPill capsule is an orally ingestible pill approximately the size of a “000” capsule (or similar to the size of a standard fish oil or calcium pill) that is designed to automatically administer a precise therapeutic dose of medication upon deployment in the small intestine. To date, we have successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using the RaniPill capsule. Our development efforts have enabled us to construct an extensive intellectual property portfolio that we believe provides us a competitive advantage.
Reviva Pharmaceuticals Holdings, Inc.
Nasdaq: RVPH
Reviva Pharmaceuticals Holdings, Inc.
Nasdaq: RVPH · OTCQB: RVPH
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Rezolute Bio
Nasdaq: RZLT
Rezolute Bio
Nasdaq: RZLT
Rezolute, Inc. (Nasdaq: RZLT) is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
scPharmaceuticals Inc.
SCPH
scPharmaceuticals Inc.
SCPH
scPharmaceuticals is a clinical-stage pharmaceutical company focused on developing and commercializing products that, through our proprietary platform, are designed to enable the subcutaneous administration of therapies previously limited to intravenous (IV) delivery — with the goal of transforming infused therapies, advancing patient care and reducing healthcare costs.
SCYNEXIS, Inc.
Nasdaq: SCYX
SCYNEXIS, Inc.
Nasdaq: SCYX
All around the world, millions of people suffer from pernicious fungal diseases.
At SCYNEXIS, we are bringing a ground-breaking class of drugs to the battle by developing innovative products that have the strength, safety and versatility to defeat even the most insidious fungal diseases.
We are committed to positively impacting the lives of patients suffering from fungal infections — from the most common to the difficult-to-treat and deadliest.
SeaStar Medical Holding Corporation
Nasdaq: ICU
SeaStar Medical Holding Corporation
Nasdaq: ICU
SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. Our first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA-approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic-like condition in critically ill pediatric patients. Our Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. We are currently conducting a pivotal trial of our SCD therapy in adult patients with AKI requiring continuous renal replacement therapy, a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.
SELLAS Life Sciences Group, Inc.
Nasdaq: SLS
SELLAS Life Sciences Group, Inc.
Nasdaq: SLS
We are a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. Our product candidates currently include galinpepimut-S, or GPS, a cancer immunotherapeutic agent that targets the Wilms tumor 1, or WT1, protein, and SLS009, a highly selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
STRATA Skin Sciences, Inc.
SSKN
STRATA Skin Sciences, Inc.
SSKN
STRATA Skin Sciences is a medical technology company focused on the therapeutic and aesthetic dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions.
Talphera, Inc.
Nasdaq: TLPH
Talphera, Inc.
Nasdaq: TLPH
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.
Tenon Medical, Inc.
Nasdaq: TNON
Tenon Medical, Inc.
Nasdaq: TNON
Delivering the latest innovation in sacroiliac joint surgical solutions, Tenon Medical is uniquely positioned to introduce a refined surgical option for patients with chronic sacroiliac joint pain that fail conservative care. The CatamaranTM SIJ Fusion System offers a patented new surgical solution that places a single implant directly into the SI joint. Tenon Medical is led by a powerful team with years of cumulative experience in designing and launching innovative surgical solutions that deliver a pathway to improved quality of life for thousands of patients.
Tivic Health Systems, Inc.
Nasdaq: TIVC
Tivic Health Systems, Inc.
Nasdaq: TIVC
Tivic Health Systems, Inc. is a commercial-stage bioelectronic medicine company focused on treating diseases and conditions by modulating the electrical signals carried along various nerve pathways.
Our first FDA-approved product, ClearUP® Sinus Pain Relief (“ClearUP”), is a patented handheld device that uses ultra-low current electrical waves to relieve sinus pain and congestion, common symptoms of sinus and nasal inflammation. These symptoms are often associated with nasal allergies, sinus infections, chronic sinusitis, cold and flu, a $9.9 billion U.S. market currently dominated by pharmaceutical companies. ClearUP, a non-invasive bioelectronic therapy, can safely and comfortably deliver therapeutic benefits with no significant side effects.
ClearUP is a US FDA Class II and EU Class IIa medical device that has received three regulatory clearances: (US FDA 510(k) number K182025, US FDA De Novo number DEN200006 and EU CE Mark Certificate number CE 704687). ClearUP is available on Amazon, Best Buy, Walgreens, Walmart and other major e-commerce websites.
TriSalus Life Sciences, Inc.
Nasdaq: TLSI
TriSalus Life Sciences, Inc.
Nasdaq: TLSI
TriSalus Life Sciences® is an oncology focused medical technology business providing disruptive drug delivery technology with the goal of improving therapeutics delivery to liver and pancreatic tumors. The Company’s platform includes devices that utilize a proprietary drug delivery technology and a clinical stage investigational immunotherapy. The Company’s two FDA-cleared devices use its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) approach to deliver a range of therapeutics: the TriNav® Infusion System for hepatic arterial infusion of liver tumors and the Pancreatic Retrograde Venous Infusion System for pancreatic tumors. PEDD is a novel delivery approach designed to address the anatomic limitations of arterial infusion for the pancreas. The PEDD approach modulates pressure and flow in a manner that delivers more therapeutic to the tumor and is designed to reduce undesired delivery to normal tissue, bringing the potential to improve patient outcomes. Nelitolimod, the Company’s investigational immunotherapeutic candidate, is designed to improve patient outcomes by treating the immunosuppressive environment created by many tumors and which can make current immunotherapies ineffective in the liver and pancreas. Patient data generated during Pressure-Enabled Regional Immuno-OncologyTM (PERIO) clinical trials support the hypothesis that nelitolimod delivered via PEDD may have favorable immune effects within the liver and systemically. The target for nelitolimod, TLR9, is expressed across cancer types and the mechanical barriers addressed by PEDD are commonly present as well. Nelitolimod delivered by PEDD will be studied across several indications in an effort to address immune dysfunction and overcome drug delivery barriers in the liver and pancreas.
TuHURA Biosciences
Nasdaq: HURA
TuHURA Biosciences
Nasdaq: HURA
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma.
In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies
Vivani Medical, Inc.
Nasdaq: VANI
Vivani Medical, Inc.
Nasdaq: VANI
Vivani Medical is an emerging biopharmaceutical company developing a pipeline of miniature, long-term drug implants with its proprietary NanoPortalTM platform technology for obesity/weight management and other chronic diseases.
Vivani’s lead drug implant candidates are designed to improve medication adherence and deliver smooth consistent therapeutic levels of GLP-1 – the same class of active pharmaceutical ingredients in Ozempic®, Trulicity® and Wegovy® – for six months or longer with a single administration. NPM-115 and NPM-119, are miniature, six-month, GLP-1 (exenatide) implants under development for obesity/chronic weight management and the treatment of type 2 diabetes, respectively.
As a result of positive preclinical weight loss data comparing NPM-115 to Ozempic/Wegovy and the transformational change in the obesity market, Vivani has decided to prioritize development of its obesity portfolio moving forward which also includes NPM-139 (semaglutide implant) with the potential for once-yearly dosing.
Vivani continues to proceed towards initiating LIBERATE-1, a First-in-Human (FIH) study assessing the exenatide implant’s safety and pharmacokinetic profile in obese and overweight individuals. In addition to an active control arm with Bydureon BCise®, LIBERATE-1 will also include a second active control arm with Wegovy (semaglutide injection).
NanoPortalTM has broad potential application across a range of molecule types including peptide therapeutics.
Zevra Therapeutics, Inc.
Nasdaq: ZVRA
Zevra Therapeutics, Inc.
Nasdaq: ZVRA
Zevra (NASDAQ GS: ZVRA) is a rare disease therapeutics company driven by science, data and patient need to create transformational therapies for diseases with limited or no treatment options.
No companies match your search.
3 DAY EVENT
With Company & Panel Discussions
80+ COMPANIES
Within the Healthcare Sector
LIVE DISCUSSIONS
Request a Meeting
Ask a Question
M-Vest is a division of Maxim Group LLC (“Maxim Group”) that serves to allow investors to access investment opportunities online and to provide a digital community built for issuers, investors, and thought leaders to share information.. Through this platform and community, we aim to redefine investment banking. The platform provides insights on current market trends through presentations from innovative emerging growth companies and commentary from industry thought leaders via live events and Q&A. Capital raisings provide an opportunity for our investor community to participate in Regulation A and Regulation D offerings.

To view Maxim Group's recent news and insights, please visit maximgrp.com.